GLP-1 Receptor Agonists: Fertility, Pregnancy Safety, and Treatment Considerations

GLP-1 receptor agonists are transforming diabetes and obesity care, but as more women of reproductive age use medications like semaglutide, liraglutide, and tirzepatide, questions about how these therapies affect fertility and pregnancy are becoming increasingly common. Understanding the reproductive implications of GLP-1 therapy is now essential for healthcare professionals managing diabetes and metabolic disease.

GLP-1 receptor agonists promote weight loss, improve insulin sensitivity, and reduce hyperglycemia. Because obesity and insulin resistance impair ovulation, improving metabolic health may indirectly enhance fertility. In women with obesity or type 2 diabetes, even modest weight reduction can significantly improve ovulatory function. GLP-1 agents help many patients reach that threshold. As a result, previously anovulatory women may resume regular cycles sooner than expected.

Although direct fertility data remain limited, small studies in women with PCOS suggest improved menstrual regularity and ovulation rates. Most large clinical trials excluded women actively attempting conception. Still, the metabolic benefits seen with GLP-1 therapy support its role in preconception optimization when carefully timed.

Importantly, improved ovulation increases the need for reliable contraception if pregnancy is not desired. Because fertility may return unpredictably, providers should address contraceptive planning at treatment initiation.

While GLP-1 agents offer meaningful metabolic benefits, they are not recommended during pregnancy. Animal studies have shown fetal growth concerns at high exposures. Therefore, current prescribing information advises discontinuation before conception.

For long-acting agents such as semaglutide, clinicians generally recommend stopping therapy at least two months before attempting pregnancy due to the extended half-life. Tirzepatide carries similar precautions. Because unplanned pregnancies occur frequently, contraception counseling should accompany every GLP-1 prescription for women of reproductive age.

If pregnancy occurs unexpectedly during therapy, the medication should be discontinued promptly. However, patients can be reassured that limited human data have not demonstrated consistent teratogenic patterns to date. Ongoing registries continue to monitor outcomes.

At the same time, glycemic control remains critical. Insulin remains the preferred treatment during pregnancy in patients with diabetes. Early coordination with obstetrics and endocrinology can help ensure safe transitions and stable glucose management.

Polycystic ovary syndrome affects up to 10% of reproductive-age women and is strongly linked to insulin resistance. Because GLP-1 receptor agonists improve insulin sensitivity and promote weight loss, they have gained attention as adjunct therapy in PCOS management.

Several studies show that liraglutide and semaglutide improve weight, waist circumference, and metabolic parameters in women with PCOS. Furthermore, some evidence suggests improved menstrual frequency and ovulatory function. When combined with metformin, outcomes may improve further in selected patients.

Although GLP-1 agents are not first-line therapy for PCOS, they may benefit women with obesity who have not responded adequately to lifestyle interventions and metformin. Therefore, reproductive considerations frequently arise in endocrine and primary care settings when prescribing these medications.

However, treatment goals must remain clear. If pregnancy is desired in the near term, timing becomes especially important. In contrast, if weight optimization is the primary objective before conception, short-term therapy followed by an appropriate washout period may be reasonable.

Preconception counseling provides a structured opportunity to address the reproductive safety of GLP-1 medications proactively. Ideally, these discussions occur before therapy begins. Clinicians should document pregnancy intentions, review contraceptive options, and outline a clear discontinuation plan if conception is desired.

In the broader treatment landscape, GLP-1 receptor agonists belong to the injectable drugs class for managing type 2 diabetes mellitus. In a glucose-dependent mechanism, GLP-1RAs act by stimulating insulin secretion and suppressing inappropriately elevated glucagon levels. These drugs are also observed to delay gastric emptying and promote satiety and are associated with a negligible risk of hypoglycemia.

Until September 2019, six different GLP-1RA formulations were available with subcutaneous administration but with different dosing regimens. However, SC treatment with GLP-1 RAs is limited by their injectable mode of administration. Patients' perception of injectable therapy includes perceived difficulty in use and fear of injections. This can affect the acceptance of or adherence to treatment by a patient with type 2 diabetes. Injectable anti-diabetes drugs had the lowest persistence at 28.7% at 1 year among treatment-naïve patients in a previous study.

The United States Food and Drug Administration approved oral semaglutide, the first GLP-1RA designed for oral administration. Certain patients may prefer oral drugs over injectables and studies have shown that patients are less likely to stick to treatment regimens that are difficult or inconvenient.